Vancouver, British Columbia - enGene Inc., a privately held biotechnology company developing an innovative platform technology to deliver nucleotides (DNA or siRNA) to mucosal tissue for treating a variety of diseases, announced today that Eric A. Adams, CEO, will present a corporate update and recent data on the Company's EG-10 program for IBD at the BioPartnering North America (BPN) conference on 28 February 2011 at 1:30pm at the Vancouver Convention Center. Additionally, the Company will be meeting individually with several leading international pharmaceutical and biotechnology companies to discuss possible partnership opportunities for its technology.
Now in its ninth year, BPN is focused on facilitating business development and offers excellent partnering opportunities for life science innovators and investors. Produced by TVG & LifeSciences British Columbia, and hosted by BIOTECanada & BioAlberta, BPN annually attracts senior business development executives from around the globe.
More about enGene
enGene Inc. has developed a highly flexible, biopolymer-based nucleotide (DNA and siRNA) delivery technology targeting mucosal tissues to treat numerous prevalent, chronic diseases via the induction or suppression of protein expression levels. Our platform technology has the ability to significantly impact diseases of mucosal tissues such as the gastrointestinal tract, lung and bladder as well as provide systemic release of proteins from the gut to treat diabetes, anemia, hemophilia and others. The two lead programs are the localized delivery of an anti-inflammatory cytokine, IL-10, for treating Inflammatory Bowel Disease and delivery of insulin in a physiologic, meal-dependent fashion to regulate blood glucose levels.
For more information please visit www.engeneinc.com.
Eric A. Adams, President and CEO, enGene Inc.
email@example.com / www.engeneinc.com